Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $71,530.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Jeanne Thoma sold 1,000 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $71.53, for a total value of $71,530.00. Following the completion of the sale, the director directly owned 26,762 shares of the company’s stock, valued at $1,914,285.86. The trade was a 3.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Up 2.1%

Shares of ANIP stock opened at $73.59 on Thursday. The stock’s fifty day moving average price is $76.47 and its 200 day moving average price is $78.11. ANI Pharmaceuticals, Inc. has a 1-year low of $69.58 and a 1-year high of $98.55. The company has a market cap of $1.69 billion, a price-to-earnings ratio of 15.86 and a beta of 0.45. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same period last year, the business posted $1.80 earnings per share. The firm’s revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership raised its position in ANI Pharmaceuticals by 19.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after buying an additional 91,153 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of ANI Pharmaceuticals by 8.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after acquiring an additional 43,523 shares during the last quarter. Ranger Investment Management L.P. purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at $28,406,000. Deutsche Bank AG acquired a new stake in shares of ANI Pharmaceuticals in the second quarter worth $26,775,000. Finally, William Blair Investment Management LLC purchased a new position in shares of ANI Pharmaceuticals during the second quarter worth $21,372,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ANIP. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 target price on the stock. Guggenheim decreased their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Canaccord Genuity Group cut their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $103.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.